Supplementary Table 6. Sensitivity analysis of clinical outcomes comparing the normoglycemic and variable hyperglycemic groups with the persistently elevated stable group in the expanded cohort

Outcomes	Normoglycemic (Group 1, n=115)		Persistently elevated stable (Group 2, n=178)	Variable hyperglycemic (Group 3, n=68)	
	Common OR or OR (95% CI)	*P**	Reference	Common OR or OR (95% CI)	*P**
Unadjusted					
3-month mRS (shift analysis)					
Unadjusted common OR (95% CI)†	2.69 (1.77–4.11)	<0.001	1 (Ref)	1.31 (0.80–2.14)	0.279
Functional independence (mRS 0–2)					
Unadjusted OR (95% CI)	2.92 (1.79–4.75)	<0.001	1 (Ref)	1.13 (0.64–2.00)	0.669
Excellent outcome (mRS 0–1)					
Unadjusted OR (95% CI)	2.11 (1.29–3.45)	0.003	1 (Ref)	1.14 (0.62–2.10)	0.666
Poor outcome (mRS 4–6)					
Unadjusted OR (95% CI)	0.30 (0.18–0.51)	<0.001	1 (Ref)	0.87 (0.50–1.52)	0.623
Symptomatic hemorrhagic transformation at day 5‡					
Unadjusted OR (95% CI)‡	0.13 (0.01–2.43)	0.173	1 (Ref)	1.17 (0.25–5.40)	0.844
Model 1§					
3-month mRS (shift analysis)					
Adjusted common OR (95% CI)	2.94 (1.87–4.61)	<0.001	1 (Ref)	1.27 (0.75–2.15)	0.369
Functional independence (mRS 0–2)					
Adjusted OR (95% CI)	3.42 (1.96–6.00)	<0.001	1 (Ref)	1.00 (0.52–1.91)	0.992
Excellent outcome (mRS 0–1)					
Adjusted OR (95% CI)	2.16 (1.23–3.79)	0.007	1 (Ref)	1.10 (0.55–2.21)	0.787
Poor outcome (mRS 4–6)					
Adjusted OR (95% CI)	0.24 (0.13–0.43)	<0.001	1 (Ref)	1.06 (0.55–2.04)	0.864
Model 2‖					
3-month mRS (shift analysis)					
Adjusted common OR (95% CI)	2.86 (1.75–4.67)	<0.001	1 (Ref)	1.46 (0.86–2.49)	0.160
Functional independence (mRS 0–2)					
Adjusted OR (95% CI)	3.77 (2.00–7.11)	<0.001	1 (Ref)	1.29 (0.65–2.57)	0.461
Excellent outcome (mRS 0–1)					
Adjusted OR (95% CI)	2.35 (1.25–4.42)	0.008	1 (Ref)	1.29 (0.63–2.65)	0.481
Poor outcome (mRS 4–6)					
Adjusted OR (95% CI)	0.22 (0.11–0.43)	<0.001	1 (Ref)	0.86 (0.44–1.71)	0.673
Model 3¶					
3-month mRS (shift analysis)					
Adjusted common OR (95% CI)	2.60 (1.58–4.29)	<0.001	1 (Ref)	1.44 (0.84–2.47)	0.185
Functional independence (mRS 0–2)					
Adjusted OR (95% CI)	3.72 (1.94–7.12)	<0.001	1 (Ref)	1.33 (0.66–2.68)	0.427
Excellent outcome (mRS 0–1)					
Adjusted OR (95% CI)	2.13 (1.11–4.08)	0.022	1 (Ref)	1.23 (0.59–2.54)	0.584
Poor outcome (mRS 4–6)					
Adjusted OR (95% CI)	0.24 (0.12–0.48)	<0.001	1 (Ref)	0.85 (0.42–1.72)	0.655

OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale; Ref, reference; NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early Computed Tomography Score; HTN, hypertension; DM, diabetes mellitus; IVT, intravenous thrombolysis; HbA1c, hemoglobin A1c.
**P*-value by ordinal logistic regression and binary logistic regression; †Common OR: ordinal shift across the range of mRS scores toward a better outcome; ‡Due to the very small number of symptomatic hemorrhagic transformation events (n=7), Firth's penalized logistic regression model was applied; §Model 1: adjusted for age, sex, initial NIHSS, and ASPECTS; ‖Model 2: adjusted for age, sex, initial NIHSS, ASPECTS, HTN, DM, and IVT; ¶Model 3: adjusted for age, sex, initial NIHSS, ASPECTS, HTN, DM, IVT, and HbA1c.